Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 3Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 1Castration-resistant Prostate Cancer 1Castration Resistant Metastatic Prostate Cancer 1

Interventions

Magnetic Resonance Spectroscopy 87Specimen Handling 76pembrolizumab 74enzalutamide 57Radiosurgery 57Radiotherapy 51Docetaxel 50Androgen Antagonists 48Gemcitabine 43Nivolumab 40darolutamide 39Prednisone 35Abiraterone Acetate 33enfortumab vedotin 32Biopsy 31Cisplatin 30Carboplatin 29apalutamide 28Standard of Care 28cabozantinib 27Pluvicto 27abiraterone 26Blood Specimen Collection 25Radiation 23Leuprolide 23Ipilimumab 23X-Rays 18relugolix 17Triptorelin Pamoate 17Surveys and Questionnaires 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × testosterone enanthate × Genitourinary × Clear all
NCT06594926 2026-04-24

WOMBAT

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Phase 2 Recruiting
69 enrolled
Genitourinary

Prostatic Neoplasms

NCT03522064 2026-04-23

HiTeCH

St Vincent's Hospital, Sydney

Phase 2 Recruiting
30 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT04363164 2026-04-06

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
150 enrolled
Genitourinary

Castration Resistant Metastatic Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡